Lifemd, Inc.

Health Information Services • Healthcare • New York, NY, United States • LFMDP (NGM)

866 351 5907 236 Fifth Avenue, New York, NY 10001, United States

Quarter: Q4 2025 Reported: November 5, 2025 Sentiment: Negative

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company operates through two operating segments: Telehealth and WorkSimpli. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation, and hair loss; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; and Cleared which provides personalized treatments for allergy, asthma and immunology. It also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. Further, it offers GLP-1 for weight management and in-home health monitoring devices. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

Analysis Summary

LifeMD, Inc. has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025, from the original November 5th date. This delay is attributed to the company identifying corrections related to revenue recognition and offsetting balance sheet accounts, which arose following recent data system migrations. The affected periods span the twelve months ending December 31, 2024, and the six months ending June 30, 2025. The cumulative financial impact of these necessary adjustments is estimated at approximately $4.6 million, which constitutes about 1.4% of the cumulative revenue reported during the specified timeframe. Management has emphasized that these adjustments are not expected to materially impact how reported revenue results compare to guidance for the respective reporting periods, nor will they affect the company's cash flow or overall cash position. The company anticipates filing a Form 12b-25 to notify the SEC of the late filing of its Form 10-Q for the period ended September 30, 2025. This announcement does not include any Q4 2025 earnings results or forward guidance for that period.

Management commentary highlighted the proactive identification of these issues and their limited financial impact on prior guidance and cash. However, the forward-looking statements section indicates that the preliminary determinations are subject to adjustment as financial statements are prepared, and these matters could potentially impact internal control over financial reporting. The company's auditors have not yet audited, reviewed, or compiled these preliminary determinations. This situation introduces a degree of uncertainty regarding the final financial statements and the integrity of internal controls, which will be a key area of focus during the upcoming earnings release. The delay and the nature of the corrections, while deemed immaterial by management, will likely draw scrutiny from investors and analysts regarding the robustness of the company's financial reporting systems.

Key Highlights

• Q3 2025 earnings release and conference call rescheduled to November 17, 2025.
• Delay due to identified corrections in revenue recognition and balance sheet accounts.
• Corrections relate to periods ending December 31, 2024, and June 30, 2025.
• Cumulative financial impact of corrections is approximately $4.6 million.
• Adjustments represent about 1.4% of cumulative revenue for the affected periods.
• Company states adjustments will not materially impact revenue guidance or cash flow/position.
• Form 12b-25 will be filed for late Q3 2025 Form 10-Q.

Financial Metrics

guidance

q4 2025 eps

N/A

YoY: N/A

q4 2025 revenue

N/A USD

YoY: N/A

q4 2025 net income

N/A USD

YoY: N/A

prior period revenue correction

4.6 million

Stock Performance (90 Days)

Data through Dec 29, 2025

Layoff Events

Earnings Calls

Positive Signals

• Proactive identification of accounting errors by the company.
• Stated immaterial impact on reported revenue compared to prior guidance.
• No impact on the company's cash flow or cash position.
• Clear communication of the reason for the delay and new dates.

Risks & Concerns

— Delay in filing of Form 10-Q for Q3 2025.
— Accounting errors, even if deemed immaterial, raise concerns about financial reporting accuracy.
— Potential impact on internal control over financial reporting, which is still under evaluation.
— Auditors have not yet reviewed the preliminary determinations, meaning final adjustments could differ.
— Uncertainty regarding investor perception due to delayed filings and accounting adjustments.